Protocol Ledger

NCT05705167 · Phase II · TERMINATED

Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care (NEREIDA)

Interventional Phase II clinical trial protocol NCT05705167 sponsored by PharmaMar in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-04-19 Enrollment: 37 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05705167
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)37 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05705167
Protocol FieldVerified Registry Value
NCT IdentifierNCT05705167
Consolidated Lead SponsorPharmaMar
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment37 participants (ACTUAL)
Registered Start Date2023-04-19
WhyStopped ClassificationInsufficient / Slow Accrual

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI